Absci Plans Phase 2 Trial for Endometriosis Drug
News related to:Absci Corporation · 3 min read
VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 /CourierPR/ -- Absci Corporation, a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis. The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
The initiation of this Phase 2 trial would be an important step toward establishing ABS-201’s ability to deliver durable relief of endometriosis-associated pain with a differentiated safety and tolerability profile. With the safety, tolerability, and pharmacokinetic (PK) data being generated for ABS-201 in the company’s ongoing HEADLINE trial, Absci anticipates initiation of this Phase 2 clinical trial for endometriosis in mid-2027. Absci is designing STORYLINE as a dose-ranging trial, anticipating testing two or three dose levels that will be confirmed following review of HEADLINE data.
The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
Absci is developing ABS-201 because it believes prolactin receptor blockade offers a fundamentally different, non-hormonal approach that may fulfill the substantial unmet clinical need facing these patients. The initiation of this Phase 2 trial would be an important step toward establishing ABS-201’s ability to deliver durable relief of endometriosis-associated pain with a differentiated safety and tolerability profile. With the safety, tolerability, and pharmacokinetic (PK) data being generated for ABS-201 in the company’s ongoing HEADLINE trial, Absci anticipates initiation of this Phase 2 clinical trial for endometriosis in mid-2027. Absci is designing STORYLINE as a dose-ranging trial, anticipating testing two or three dose levels that will be confirmed following review of HEADLINE data.
Absci Corporation, a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis. The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
Absci anticipates initiating this Phase 2 clinical trial for endometriosis in mid-2027, subject to regulatory clearance and protocol finalization. The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
Absci is designing STORYLINE as a dose-ranging trial, anticipating testing two or three dose levels that will be confirmed following review of HEADLINE data. The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.
Absci anticipates initiating this Phase 2 clinical trial for endometriosis in mid-2027, subject to regulatory clearance and protocol finalization.